355 related articles for article (PubMed ID: 26929256)
21. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.
Redahan L; Davenport A
J Nephrol; 2016 Jun; 29(3):427-434. PubMed ID: 26616639
[TBL] [Abstract][Full Text] [Related]
22. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
23. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
Moriishi M; Kawanishi H; Tsuchiya S
Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
Shimada S; Mori T; Koizumi K; Sato S; Oba-Yabana I; Ohsaki Y; Sato E; Naganuma E; Kurasawa N; Tsuchikawa M; Ito S
Adv Perit Dial; 2016; 32():46-50. PubMed ID: 28988589
[TBL] [Abstract][Full Text] [Related]
26. Effect of bicarbonate/lactate peritoneal dialysis solutions on human mesothelial cell proliferation ex vivo.
Bajo MA; del Peso G; Castro MA; Díaz C; Castro MJ; Gil F; Sánchez-Tomero JA; Selgas R
Adv Perit Dial; 2001; 17():37-41. PubMed ID: 11510293
[TBL] [Abstract][Full Text] [Related]
27. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
Skoufos L; Topley N; Cooker L; Dawnay A; Millar DJ; Holmes CJ; Faict D
Kidney Int Suppl; 2003 Dec; (88):S94-9. PubMed ID: 14870882
[TBL] [Abstract][Full Text] [Related]
28. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
29. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
30. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?
Chung SH; Stenvinkel P; Bergström J; Lindholm B
Perit Dial Int; 2000; 20 Suppl 5():S57-67. PubMed ID: 11229614
[TBL] [Abstract][Full Text] [Related]
31. Short- and medium-term increase of CA125 in peritoneal effluent using a neutral-pH solution.
García H; Hernández-Jaras J; Cruz Mdel C; Agramunt I; Calvo C; Cerrillo V
Perit Dial Int; 2003; 23(4):375-80. PubMed ID: 12968846
[TBL] [Abstract][Full Text] [Related]
32. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.
Yoon HE; Chang YK; Shin SJ; Choi BS; Kim BS; Park CW; Song HC; Yoon SA; Jin DC; Kim YS
J Korean Med Sci; 2014 Sep; 29(9):1217-25. PubMed ID: 25246739
[TBL] [Abstract][Full Text] [Related]
33. Icodextrin and intraperitoneal inflammation.
Moriishi M; Kawanishi H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
[TBL] [Abstract][Full Text] [Related]
34. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
35. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.
Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC
Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303
[TBL] [Abstract][Full Text] [Related]
36. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.
Weiss L; Stegmayr B; Malmsten G; Tejde M; Hadimeri H; Siegert CE; Ahlmén J; Larsson R; Ingman B; Simonsen O; van Hamersvelt HW; Johansson AC; Hylander B; Mayr M; Nilsson PH; Andersson PO; De los Ríos T
Perit Dial Int; 2009; 29(6):647-55. PubMed ID: 19910566
[TBL] [Abstract][Full Text] [Related]
37. The effect of dwell time on dialysate cancer antigen 125 appearance rates in patients on continuous ambulatory peritoneal dialysis.
Akman S; van Westrhenen R; De Waart DR; Hiralall JK; Zweers MM; Krediet RT
Adv Perit Dial; 2003; 19():24-7. PubMed ID: 14763029
[TBL] [Abstract][Full Text] [Related]
38. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
[TBL] [Abstract][Full Text] [Related]
39. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.
van Esch S; Zweers MM; Jansen MA; de Waart DR; van Manen JG; Krediet RT
Perit Dial Int; 2004; 24(6):554-61. PubMed ID: 15559485
[TBL] [Abstract][Full Text] [Related]
40. Studying the effects of new peritoneal dialysis solutions on the peritoneum.
Chan TM; Yung S
Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
